Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Autolus Therapeutics plcNASDAQ: AUTL
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $3.57M rose 24.3% year over year, ahead of the -5.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at +6.3% a year.
Context
- Stock-based compensation amounted to 19.1% of revenue in FY2025, down 133.8 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +24.3% holds above the trailing-twelve-month pace of -5.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 14.44M USD
- Year-over-year change
- -6.7%
- 4-year CAGR
- +9.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.44M | -6.7% |
| FY2024 | 2024-12-31 | 15.47M | +38.1% |
| FY2023 | 2023-12-31 | 11.2M | -6.7% |
| FY2022 | 2022-12-31 | 12.01M | +20.9% |
| FY2021 | 2021-12-31 | 9.94M | — |
Stock-Based Compensation vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 stock-based compensation of $15.14M is the 4th largest of the 10 companies compared; the peer median is $8.91M.
- Its year-over-year change of -5.7% is the 2nd highest of 10, against a peer median of -43.3%.
- Stock-based compensation amounts to 16.3% of revenue for AUTL, versus a peer median of 27.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.81M | +19.3% | — | 115500.0% | |
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $21.47M | -43.3% | -31.8% | 340.0% | |
| LTM Mar 2026 | $15.14M | -5.7% | +6.3% | 16.3% | |
| LTM Mar 2026 | $11.16M | -32.8% | +2.7% | 99.6% | |
| LTM Mar 2026 | $8.91M | -28.8% | -19.0% | 19.8% | |
| LTM Sep 2026 | $7.7M | -87.8% | — | 0.6% | |
| LTM Mar 2026 | $6.29M | -72.4% | -43.4% | 27.2% | |
| LTM Mar 2026 | $5.86M | -50.8% | -13.8% | — | |
| LTM Mar 2026 | $1.28M | -60.6% | — | 1.9% | |
| Peer median (excluding AUTL) | $8.91M | -43.3% | -21.2% | 27.2% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (287.53M) |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.81M |
| Deferred Income Tax | (72K) | (268K) | (986K) | (185K) | (286K) |
| Stock-Based Compensation | 9.94M | 12.01M | 11.2M | 15.47M | 14.44M |
| Change in Working Capital | 4.14M | 3.97M | 292K | (23.66M) | (52.11M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (24.21M) |
| Inventory | 0 | 0 | 0 | (4.23M) | (40.34M) |
| Accounts Payables | (1.82M) | 22K | (509K) | 1.59M | 1.3M |
| Other Working Capital | 5.95M | 3.95M | 801K | (21.02M) | 11.14M |
| Other Non-Cash Items | 1.77M | 13.4M | 45.72M | 15.04M | 32.1M |
| Operating Cash Flow | (117.86M) | (112.31M) | (145.59M) | (206.27M) | (283.57M) |
| Capital Expenditures | (8.86M) | (10.84M) | (10.99M) | (34.82M) | (27.13M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (359.73M) | (242.62M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 428.21M |
| Other Investing Activities | 0 | 0 | 0 | (12.74M) | (8.09M) |
| Investing Cash Flow | (8.86M) | (10.84M) | (10.99M) | (394.55M) | 158.46M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 245.9M | 163.85M | 0 | 549.98M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 38.16M | 59.76M | (883K) | 39.58M | (4.34M) |
| Financing Cash Flow | 284.06M | 223.61M | (883K) | 589.55M | (4.34M) |
| Effect of Forex Changes | (754K) | (28.38M) | 15.03M | (261K) | 6.28M |
| Net Change in Cash | 156.59M | 72.09M | (142.43M) | (11.53M) | (123.17M) |
| Free Cash Flow | (126.72M) | (123.15M) | (156.57M) | (241.09M) | (310.7M) |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.